Page 3 of 6
External Advisors
Upon the execution of this Letter of Intent, Azurite intends to engage third-party professionals such as attorneys, accountants and insurance and benefits professionals to assist us in our evaluation of the risks and opportunities.
Definitive Agreements
Upon execution of this Letter of Intent, we would propose that our respective legal counsel immediately begin negotiating a definitive purchase agreement, along with all other ancillary legal agreements (collectively, the “Definitive Agreements”) so that we would be able to close the transaction within the time frame discussed herein. The Definitive Agreements will contain customary agreements, conditions, representations, warranties, indemnities and escrows of the parties.
Process and Timing
We would anticipate signing the Definitive Agreements within 25 days, and closing the transaction within a total of 30 days, subject only to any required regulatory or legal approvals or consents.
Confidentiality
This Letter of Intent shall be subject to that certain Confidentiality Agreement, dated as of March 15, 2024, by and between Invacare and Azurite, which is incorporated herein by reference.
Exclusivity
The Company agrees that unless negotiations between Invacare and Azurite are earlier terminated by mutual agreement, Invacare shall not, and shall not permit any of its affiliates or representatives to, entertain, solicit, discuss, facilitate, enable or pursue a possible merger, equity sale, asset sale, recapitalization or other material transaction involving Invacare or the North American business (an “Alternative Transaction”) for a 60-day period beginning on the date upon which Azurite and Invacare execute this Letter of Intent (the “Exclusivity Period”). The Exclusivity Period may be extended by mutual agreement if, during the initial period, Buyer and Seller have worked together in good faith and made meaningful progress toward a closing of the transaction.
If the Company or any of its representatives receives any inquiries or solicitations involving an Alternative Transaction at any time during the Exclusivity Period, then the Company, as applicable, will promptly notify Azurite in writing of such inquiry or solicitation and supply comprehensive details of the Alternative Transaction, including, if applicable, a copy of the alternative proposal.
Fees and Expenses
Except as otherwise provided in the Definitive Agreements, Azurite and Invacare agree to each pay their respective fees and expenses incurred in connection with the transaction, including, without limitation, fees and expenses of investment bankers, brokers, legal counsel, accountants, consultants, appraisers and other professionals, and will not look to the other party for any contribution toward such expenses, except that if Invacare breaches the obligation set forth under “Exclusivity” above, then, Invacare will reimburse Azurite for all such expenses incurred by Azurite in connection with the contemplated transaction.
| | | | |
Azurite Management LLC | | 25101 Chagrin Blvd. Suite 330 | | Cleveland, OH 44122 |